Gene
MSH3
MSH3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (2), Actionable biomarkers (1), Trial mentions (7), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention MSH3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
MSH3 has 7 trial mentions across 5 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 7 of 11,460 | 0.06% |
| 2022 | 1 of 8,285 | 0.01% | 7 of 13,598 | 0.05% |
| 2021 | 1 of 8,692 | 0.01% | 10 of 15,045 | 0.07% |
| 2020 | 0 of 7,640 | 0.00% | 5 of 14,459 | 0.03% |
| 2019 | 0 of 7,300 | 0.00% | 3 of 12,159 | 0.02% |
| 2018 | 3 of 6,927 | 0.04% | 6 of 11,854 | 0.05% |
| 2017 | 1 of 6,558 | 0.02% | 3 of 11,595 | 0.03% |
Showing 10 of 37 years.
Assay-provider ledger (2)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Illumina | Unclassified | Analytical validation | 1 | January 31, 2017 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Analytical validation | 1 | January 31, 2017 |
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| MSH3 oncogenic mutation | Dna-pkc Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (7)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03452774 | Trial eligibility (AACT) |
| NCT05420064 | Trial eligibility (AACT) |
| NCT03547999 | Trial eligibility (AACT) |
| NCT02992964 | Trial eligibility (AACT) |
| NCT03751761 | Trial eligibility (AACT) |
Showing 5 of 7 trial mentions.
Target-disease associations (166)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 1-myristoyl-2-linoleoyl-GPC (14:0/18:2) measurement | measurement | GWAS credible sets |
| APC-related attenuated familial adenomatous polyposis | cancer or benign tumor | Mouse knockout (IMPC) |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Aniridia-intellectual disability syndrome | disorder of visual system | Mouse knockout (IMPC) |
Showing 5 of 166 associations.
Vendor sourcing (52)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: Canonical splice site: predicted to alter splicing and result in a ... | View ClinVar record SCV007607752.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The MSH3 c.1571A>C; p.Asn524Thr variant (rs55724159) is reported in the literature in a case of unselected colorectal cancer (DeRycke 2017). However, this va... | View ClinVar record SCV001159975.2 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1060_1092dup33 variant (also known as p.V354_S364dup), located in coding exon 7 of the MSH3 gene, results from an in-frame duplication of 33 nucleotide... | View ClinVar record SCV001169925.6 |
| Asan Medical Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Written informed consent and any locally-required authorization obtained from the subject prior to performing any protocol-related procedures, includin... | View trial NCT03751761 |
| Asan Medical Center | Trial sponsor | Mentioned in trial textTrial free-text mention | MSH3 | View trial NCT03751761 |
Showing 5 of 52 sourcing records.
Trial-cited literature (76)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. | BMC medicine | 2024 | 38 |
| From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research. | International journal of molecular sciences | 2023 | 111 |
| Early-Onset Colorectal Cancer: Current Insights. | Cancers | 2023 | 70 |
| Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2023 | 56 |
| Multilevel proteomic analyses reveal molecular diversity between diffuse-type and intestinal-type gastric cancer. | Nature communications | 2023 | 47 |
Showing 5 of 76 papers.
Protein variant mentions (40)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1064V | 1 | 2016 | PMID 26467025 |
| p.A22G | 1 | 2015 | PMID 25741868 |
| p.A61T | 2 | 2015 to 2016 | PMID 26467025, PMID 25741868 |
| p.D1000E | 1 | 2015 | PMID 25741868 |
| p.D194E | 1 | 2015 | PMID 25741868 |
Showing 5 of 40 variants.
Literature-extracted relations (3)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Squamous Cell Carcinoma of Head and Neck | Disease | associate |
The DNA damage response network in the treatment of head and neck squamous cell carcinoma. | 2021 |
| Microsatellite Instability | Disease | associate |
Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) Is Not Attributed to MSH3 Loss in Stage I-III Colon cancer: An Automated, Digitalized Assessment by Immunohistochemistry of Whole Slides and Hot Spots. | 2019 |
| Neoplasms | Disease | associate |
Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) Is Not Attributed to MSH3 Loss in Stage I-III Colon cancer: An Automated, Digitalized Assessment by Immunohistochemistry of Whole Slides and Hot Spots. | 2019 |
Organizations publishing (156)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 6 | 2010 to 2022 |
| Mayo Clinic | Hospital | 6 | 2016 to 2022 |
| The University of Texas System | Academic | 4 | 2015 to 2023 |
| Chinese Academy of Medical Sciences & Peking Union Medical College | Academic | 3 | 2014 to 2024 |
| Dana-Farber Cancer Institute | Other | 3 | 2015 to 2022 |
Showing 5 of 156 organizations.
Where MSH3 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- measurement
- nervous system disease
- phenotype
- respiratory or thoracic disease
153 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.